{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:53:28Z","timestamp":1789786408767,"version":"4.0.1"},"reference-count":167,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.2215\/cjn.10941013","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:40:59Z","timestamp":1393548059000},"page":"1283-1303","source":"Crossref","is-referenced-by-count":50,"title":["The Use of Fibroblast Growth Factor 23 Testing in Patients with Kidney Disease"],"prefix":"10.2215","volume":"9","author":[{"given":"Edward R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20230601","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"key":"R2-21-20230601","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R3-21-20230601","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"R4-21-20230601","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"R5-21-20230601","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R7-21-20230601","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"R8-21-20230601","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int"},{"key":"R9-21-20230601","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bone.2004.04.002","article-title":"FGF23 is processed by proprotein convertases but not by PHEX.","volume":"35","author":"Benet-Pag\u00e8s","year":"2004","journal-title":"Bone"},{"key":"R10-21-20230601","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/endo.143.8.8795","article-title":"Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.","volume":"143","author":"Shimada","year":"2002","journal-title":"Endocrinology"},{"key":"R11-21-20230601","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1515\/cclm-2013-0208","article-title":"Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs.","volume":"51","author":"Smith","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"R12-21-20230601","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11255-013-0451-x","article-title":"FGF23 concentrations measured using \u201cintact\u201d assays similar but not interchangeable.","volume":"45","author":"Sinha","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"R13-21-20230601","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cca.2011.02.009","article-title":"Instability of fibroblast growth factor-23 (FGF-23): Implications for clinical studies.","volume":"412","author":"Smith","year":"2011","journal-title":"Clin Chim Acta"},{"key":"R14-21-20230601","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"R15-21-20230601","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R16-21-20230601","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jbmr.1546","article-title":"Mechanism of FGF23 processing in fibrous dysplasia.","volume":"27","author":"Bhattacharyya","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R17-21-20230601","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1210\/en.2005-0431","article-title":"Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed.","volume":"146","author":"Larsson","year":"2005","journal-title":"Endocrinology"},{"key":"R18-21-20230601","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00424-007-0231-5","article-title":"Biological activity of FGF-23 fragments.","volume":"454","author":"Berndt","year":"2007","journal-title":"Pflugers Arch"},{"key":"R19-21-20230601","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-21-20230601","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23 measurements.","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-21-20230601","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1258\/acb.2012.011274","article-title":"Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.","volume":"49","author":"Fischer","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"R22-21-20230601","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2215\/CJN.04730510","article-title":"Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.","volume":"6","author":"Vervloet","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-21-20230601","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2007060673","article-title":"Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.","volume":"19","author":"Isakova","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R24-21-20230601","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jcp.42.2.172","article-title":"Diurnal variations in serum biochemical and haematological measurements.","volume":"42","author":"Pocock","year":"1989","journal-title":"J Clin Pathol"},{"key":"R25-21-20230601","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2215\/CJN.09471209","article-title":"Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.","volume":"5","author":"Gardham","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-21-20230601","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/000456329403100105","article-title":"Seasonal variation in serum 25-hydroxy vitamin D3 does not affect 1,25-dihydroxy vitamin D.","volume":"31","author":"Hine","year":"1994","journal-title":"Ann Clin Biochem"},{"key":"R27-21-20230601","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/10408368909106595","article-title":"Generation and application of data on biological variation in clinical chemistry.","volume":"27","author":"Fraser","year":"1989","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R28-21-20230601","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2215\/CJN.13021212","article-title":"Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients.","volume":"8","author":"Seiler","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R29-21-20230601","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/j.ajkd.2012.12.013","article-title":"Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: Implications for clinical decision making.","volume":"61","author":"Cavalier","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R30-21-20230601","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000350537","article-title":"Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients.","volume":"37","author":"Jia","year":"2013","journal-title":"Am J Nephrol"},{"key":"R31-21-20230601","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","article-title":"Evaluation of a new automated chemiluminescence immunoassay for FGF23.","volume":"30","author":"Shimizu","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"R32-21-20230601","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.09580911","article-title":"PTH\u2014a particularly tricky hormone: Why measure it at all in kidney patients?","volume":"8","author":"Garrett","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R33-21-20230601","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1373\/clinchem.2011.180562","article-title":"25-hydroxyvitamin D: A difficult analyte.","volume":"58","author":"Carter","year":"2012","journal-title":"Clin Chem"},{"key":"R34-21-20230601","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease.","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"R36-21-20230601","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2215\/CJN.08680811","article-title":"Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.","volume":"7","author":"Nakano","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R37-21-20230601","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jbmr.516","article-title":"Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.","volume":"27","author":"Stubbs","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R38-21-20230601","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.","volume":"95","author":"Shimada","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-21-20230601","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.2215\/CJN.04290511","article-title":"Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.","volume":"6","author":"Isakova","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R40-21-20230601","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2008-0326","article-title":"Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.","volume":"94","author":"Wesseling-Perry","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-21-20230601","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000093277","article-title":"FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation.","volume":"104","author":"Pande","year":"2006","journal-title":"Nephron Physiol"},{"key":"R42-21-20230601","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bone.2012.02.634","article-title":"Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.","volume":"50","author":"Nakano","year":"2012","journal-title":"Bone"},{"key":"R43-21-20230601","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"R44-21-20230601","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1681\/ASN.2010080894","article-title":"Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.","volume":"22","author":"Wolf","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R45-21-20230601","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.2215\/CJN.01880213","article-title":"Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation.","volume":"8","author":"Baia","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R46-21-20230601","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1681\/ASN.2012070713","article-title":"Mineral metabolites and CKD progression in African Americans.","volume":"24","author":"Scialla","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R47-21-20230601","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bone.2012.05.017","article-title":"FGF23 adds value to risk prediction in patients with chronic kidney disease.","volume":"51","author":"Smith","year":"2012","journal-title":"Bone"},{"key":"R48-21-20230601","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.10331011","article-title":"FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.","volume":"7","author":"Lundberg","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R49-21-20230601","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2215\/CJN.04250510","article-title":"FGF-23 as a predictor of renal outcome in diabetic nephropathy.","volume":"6","author":"Titan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R50-21-20230601","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2215\/CJN.08070811","article-title":"Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women.","volume":"7","author":"Semba","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R51-21-20230601","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2215\/CJN.00550112","article-title":"FGF-23 levels in patients with AKI and risk of adverse outcomes.","volume":"7","author":"Leaf","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R53-21-20230601","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease.","volume":"50","author":"Weiner","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R54-21-20230601","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCHEARTFAILURE.112.000105","article-title":"FGF23 modifies the relationship between vitamin D and cardiac remodeling.","volume":"6","author":"Ky","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R55-21-20230601","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.2012090894","article-title":"Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes.","volume":"24","author":"Dominguez","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R56-21-20230601","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.ajkd.2012.04.014","article-title":"Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease.","volume":"60","author":"Kendrick","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R57-21-20230601","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"R58-21-20230601","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R59-21-20230601","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study.","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"key":"R60-21-20230601","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).","volume":"60","author":"Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R61-21-20230601","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/eurheartj\/ehr215","article-title":"The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.","volume":"32","author":"Seiler","year":"2011","journal-title":"Eur Heart J"},{"key":"R62-21-20230601","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00467-012-2224-7","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.","volume":"27","author":"Seeherunvong","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R63-21-20230601","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2012.06.022","article-title":"Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.","volume":"61","author":"Smith","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R64-21-20230601","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"R65-21-20230601","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1253\/circj.CJ-10-0355","article-title":"Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T.","volume":"74","author":"Negishi","year":"2010","journal-title":"Circ J"},{"key":"R66-21-20230601","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1681\/ASN.V1251079","article-title":"Left ventricular hypertrophy in the renal patient.","volume":"12","author":"Middleton","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R68-21-20230601","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R69-21-20230601","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23.","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"R70-21-20230601","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease.","volume":"22","author":"Hu","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R71-21-20230601","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ki.2010.260","article-title":"Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients.","volume":"78","author":"Krajisnik","year":"2010","journal-title":"Kidney Int"},{"key":"R72-21-20230601","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2013.09.002","article-title":"Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.","volume":"231","author":"Jovanovich","year":"2013","journal-title":"Atherosclerosis"},{"key":"R73-21-20230601","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"R74-21-20230601","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2215\/CJN.09570912","article-title":"Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.","volume":"8","author":"\u00c4rnl\u00f6v","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R75-21-20230601","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ki.2012.327","article-title":"Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.","volume":"83","author":"\u00c4rnl\u00f6v","year":"2013","journal-title":"Kidney Int"},{"key":"R76-21-20230601","doi-asserted-by":"crossref","first-page":"e44161","DOI":"10.1371\/journal.pone.0044161","article-title":"A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.","volume":"7","author":"Dai","year":"2012","journal-title":"PLoS One"},{"key":"R77-21-20230601","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.13281211","article-title":"Fibroblast growth factor 23 and Inflammation in CKD.","volume":"7","author":"Munoz Mendoza","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R78-21-20230601","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrneph.2013.147","article-title":"FGF-23 and secondary hyperparathyroidism in chronic kidney disease.","volume":"9","author":"Silver","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"R79-21-20230601","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","article-title":"Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.","volume":"45","author":"Pereira","year":"2009","journal-title":"Bone"},{"key":"R80-21-20230601","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.","volume":"26","author":"Moe","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R81-21-20230601","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ki.2013.150","article-title":"Plasma FGF23 levels increase rapidly after acute kidney injury.","volume":"84","author":"Christov","year":"2013","journal-title":"Kidney Int"},{"key":"R82-21-20230601","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.bone.2007.01.017","article-title":"Mineralized tissue cells are a principal source of FGF23.","volume":"40","author":"Yoshiko","year":"2007","journal-title":"Bone"},{"key":"R83-21-20230601","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000210389","article-title":"Regulation of fibroblast growth factor 23 production in bone in uremic rats.","volume":"111","author":"Saji","year":"2009","journal-title":"Nephron, Physiol"},{"key":"R84-21-20230601","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R85-21-20230601","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bone.2004.06.014","article-title":"Bone as a source of FGF23: Regulation by phosphate?","volume":"35","author":"Mirams","year":"2004","journal-title":"Bone"},{"key":"R87-21-20230601","doi-asserted-by":"crossref","first-page":"e70775","DOI":"10.1371\/journal.pone.0070775","article-title":"Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ace inhibitor.","volume":"8","author":"Zanchi","year":"2013","journal-title":"PLoS One"},{"key":"R89-21-20230601","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00467-013-2547-z","article-title":"FGF23 and mineral metabolism in the early post-renal transplantation period.","volume":"28","author":"Wesseling-Perry","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"R90-21-20230601","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.","volume":"6","author":"Moe","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R91-21-20230601","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.09250912","article-title":"Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.","volume":"8","author":"Isakova","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R92-21-20230601","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2215\/CJN.07640711","article-title":"Acute effects of very-low-protein diet on FGF23 levels: A randomized study.","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R93-21-20230601","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R94-21-20230601","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ndt\/gfs405","article-title":"Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): Results of a randomized trial.","volume":"28","author":"Sigrist","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R95-21-20230601","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1210\/en.2013-1627","article-title":"Calcium regulates FGF-23 expression in bone.","volume":"154","author":"David","year":"2013","journal-title":"Endocrinology"},{"key":"R97-21-20230601","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/ndt\/gfq053","article-title":"Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study.","volume":"25","author":"Brandenburg","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R98-21-20230601","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000351811","article-title":"Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.","volume":"123","author":"Spatz","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"R99-21-20230601","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD.","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R100-21-20230601","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R101-21-20230601","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2215\/CJN.11181012","article-title":"24-hour urine phosphorus excretion and mortality and cardiovascular events.","volume":"8","author":"Palomino","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R102-21-20230601","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.2215\/CJN.02740311","article-title":"Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.","volume":"6","author":"Gutierrez","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R103-21-20230601","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ki.2013.110","article-title":"Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure.","volume":"84","author":"Maizel","year":"2013","journal-title":"Kidney Int"},{"key":"R104-21-20230601","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ki.2013.194","article-title":"Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.","volume":"84","author":"Zhang","year":"2013","journal-title":"Kidney Int"},{"key":"R105-21-20230601","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial.","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R106-21-20230601","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.","volume":"7","author":"Vlassara","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R107-21-20230601","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3 CKD.","volume":"24","author":"Chue","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R108-21-20230601","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00774-007-0779-3","article-title":"Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans.","volume":"25","author":"Ito","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"R109-21-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"R110-21-20230601","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","article-title":"Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.","volume":"27","author":"Hansen","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R111-21-20230601","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"R112-21-20230601","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"R113-21-20230601","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cvr\/cvr133","article-title":"Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats.","volume":"91","author":"Bae","year":"2011","journal-title":"Cardiovasc Res"},{"key":"R114-21-20230601","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2353\/ajpath.2010.091292","article-title":"Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.","volume":"177","author":"Kong","year":"2010","journal-title":"Am J Pathol"},{"key":"R115-21-20230601","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial.","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"R116-21-20230601","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2014The OPERA Trial.","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R117-21-20230601","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2012-2790","article-title":"Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.","volume":"98","author":"Turner","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R118-21-20230601","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/00365513.2012.744464","article-title":"Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5.","volume":"73","author":"Gravesen","year":"2013","journal-title":"Scand J Clin Lab Invest"},{"key":"R119-21-20230601","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000354717","article-title":"Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: A randomized, double-blind, placebo-controlled clinical trial.","volume":"123","author":"Seibert","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"R120-21-20230601","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1210\/me.2003-0048","article-title":"Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system.","volume":"17","author":"Tsujikawa","year":"2003","journal-title":"Mol Endocrinol"},{"key":"R121-21-20230601","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/01.HYP.0000013734.33441.EA","article-title":"In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage.","volume":"39","author":"Mitani","year":"2002","journal-title":"Hypertension"},{"key":"R122-21-20230601","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/ndt\/gfq537","article-title":"Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy.","volume":"26","author":"Yoon","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R123-21-20230601","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ki.2012.322","article-title":"Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.","volume":"82","author":"Lau","year":"2012","journal-title":"Kidney Int"},{"key":"R125-21-20230601","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2369-14-112","article-title":"Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: A randomized controlled study.","volume":"14","author":"Kim","year":"2013","journal-title":"BMC Nephrol"},{"key":"R126-21-20230601","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R127-21-20230601","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R128-21-20230601","doi-asserted-by":"crossref","first-page":"F1315","DOI":"10.1152\/ajprenal.00552.2009","article-title":"Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.","volume":"298","author":"Finch","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R129-21-20230601","doi-asserted-by":"crossref","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","article-title":"PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop.","volume":"299","author":"Lavi-Moshayoff","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R130-21-20230601","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bone.2011.06.025","article-title":"Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.","volume":"49","author":"Rhee","year":"2011","journal-title":"Bone"},{"key":"R131-21-20230601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/jc.2008-0220","article-title":"Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen\u2019s metaphyseal chondrodysplasia.","volume":"94","author":"Brown","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R132-21-20230601","doi-asserted-by":"crossref","first-page":"F1212","DOI":"10.1152\/ajprenal.00169.2010","article-title":"Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.","volume":"299","author":"Saji","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"R133-21-20230601","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.06240611","article-title":"(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.","volume":"7","author":"Guti\u00e9rrez","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R134-21-20230601","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1210\/en.2009-0472","article-title":"Bone formation regulates circulating concentrations of fibroblast growth factor 23.","volume":"150","author":"Samadfam","year":"2009","journal-title":"Endocrinology"},{"key":"R135-21-20230601","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ki.2011.107","article-title":"Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.","volume":"80","author":"L\u00f3pez","year":"2011","journal-title":"Kidney Int"},{"key":"R136-21-20230601","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1359\/jbmr.090406","article-title":"Effects of hPTH(1\u201334) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men.","volume":"24","author":"Burnett-Bowie","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R137-21-20230601","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3\u20134 chronic kidney disease.","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int"},{"key":"R138-21-20230601","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"R139-21-20230601","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kft161","article-title":"Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction.","volume":"135","author":"Yanochko","year":"2013","journal-title":"Toxicol Sci"},{"key":"R140-21-20230601","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/acb.2009.009066","article-title":"Determination of fibroblast growth factor 23.","volume":"46","author":"Heijboer","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"R141-21-20230601","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study.","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R142-21-20230601","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R144-21-20230601","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000353569","article-title":"Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.","volume":"38","author":"Seifert","year":"2013","journal-title":"Am J Nephrol"},{"key":"R145-21-20230601","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R146-21-20230601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.","volume":"80","author":"Soriano","year":"2013","journal-title":"Clin Nephrol"},{"key":"R147-21-20230601","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"R148-21-20230601","doi-asserted-by":"crossref","first-page":"c74","DOI":"10.1159\/000319650","article-title":"Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate.","volume":"117","author":"Cancela","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R149-21-20230601","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: A crossover study.","volume":"78","author":"Toida","year":"2012","journal-title":"Clin Nephrol"},{"key":"R150-21-20230601","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ndt\/gfp220","article-title":"Phosphate levels\u2014time for a rethink?","volume":"24","author":"Becker","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R151-21-20230601","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/cclm.2011.880","article-title":"Diurnal variability of total calcium during normal sleep and after an acute shift of sleep.","volume":"50","author":"Ridefelt","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"R152-21-20230601","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI113172","article-title":"Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D.","volume":"80","author":"Portale","year":"1987","journal-title":"J Clin Invest"},{"key":"R153-21-20230601","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1172\/JCI107010","article-title":"Circadian rhythm in serum parathyroid hormone concentration in human subjects: Correlation with serum calcium, phosphate, albumin, and growth hormone levels.","volume":"51","author":"Jubiz","year":"1972","journal-title":"J Clin Invest"},{"key":"R154-21-20230601","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.07020711","article-title":"Racial differences in markers of mineral metabolism in advanced chronic kidney disease.","volume":"7","author":"Jovanovich","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R155-21-20230601","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ki.2008.4","article-title":"Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease.","volume":"73","author":"Guti\u00e9rrez","year":"2008","journal-title":"Kidney Int"},{"key":"R156-21-20230601","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/eje.0.1460635","article-title":"Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: Relationship to plasma parathyroid hormone and calcium and phosphate metabolism.","volume":"146","author":"Rejnmark","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"R157-21-20230601","first-page":"244","article-title":"Intraoperative monitoring of parathyroid hormone with a rapid automated assay that is commercially available.","volume":"32","author":"Kao","year":"2002","journal-title":"Ann Clin Lab Sci"},{"key":"R158-21-20230601","first-page":"281","article-title":"The parathyroid hormone circadian rhythm is truly endogenous\u2014a general clinical research center study.","volume":"82","author":"el-Hajj Fuleihan","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"R159-21-20230601","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1210\/jc.2006-2865","article-title":"Determination of the elimination half-life of fibroblast growth factor-23.","volume":"92","author":"Khosravi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R160-21-20230601","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.ajkd.2008.01.017","article-title":"Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study.","volume":"51","author":"Joly","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R161-21-20230601","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1258\/000456307780480927","article-title":"The effect of potassium EDTA on the stability of parathyroid hormone in whole blood.","volume":"44","author":"English","year":"2007","journal-title":"Ann Clin Biochem"},{"key":"R162-21-20230601","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1258\/0004563041201464","article-title":"The measurement of vitamin D: Analytical aspects.","volume":"41","author":"Zerwekh","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"R163-21-20230601","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1980.85","article-title":"Renal toxicity of phosphate in rats.","volume":"17","author":"Haut","year":"1980","journal-title":"Kidney Int"},{"key":"R164-21-20230601","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1373\/clinchem.2011.176545","article-title":"Accuracy of 6 routine 25-hydroxyvitamin D assays: Influence of vitamin D binding protein concentration.","volume":"58","author":"Heijboer","year":"2012","journal-title":"Clin Chem"},{"key":"R165-21-20230601","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1373\/clinchem.2006.071589","article-title":"Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions.","volume":"52","author":"Cantor","year":"2006","journal-title":"Clin Chem"},{"key":"R166-21-20230601","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1258\/acb.2011.011094","article-title":"Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease.","volume":"49","author":"Almond","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"R167-21-20230601","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2009.374","article-title":"Parathyroid hormone measurement in CKD.","volume":"77","author":"Souberbielle","year":"2010","journal-title":"Kidney Int"},{"key":"R168-21-20230601","first-page":"3923","article-title":"Accumulation of a non-(1\u201384) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values.","volume":"81","author":"Brossard","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R169-21-20230601","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis.","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"key":"R170-21-20230601","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study.","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R171-21-20230601","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease.","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R172-21-20230601","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2013.145","article-title":"No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.","volume":"84","author":"Mehrotra","year":"2013","journal-title":"Kidney Int"},{"key":"R173-21-20230601","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.ajkd.2011.03.020","article-title":"Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies.","volume":"58","author":"Pilz","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R174-21-20230601","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00467-012-2347-x","article-title":"Phosphate is a vascular toxin.","volume":"28","author":"Shroff","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"R175-21-20230601","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1523-1755.2004.66013.x","article-title":"Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.","volume":"66","author":"Neves","year":"2004","journal-title":"Kidney Int"},{"key":"R176-21-20230601","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/07853890.2010.543923","article-title":"Extra-skeletal effects of vitamin D deficiency in chronic kidney disease.","volume":"43","author":"Chonchol","year":"2011","journal-title":"Ann Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201407000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:12Z","timestamp":1786369452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201407000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":167,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.10941013","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}